Sanofi pulls Anzemet from five markets after FDA warning

Sanofi-Aventis (SNY) is withdrawing its anti-nausea drug Anzemet from five of the 13 countries in which it is sold, pulling the drug from markets where it is only prescribed for post-chemotherapy use, rather than post-operative nausea, after FDA warned that the drug could increase the risk of an abnormal heart rhythm. Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.